Description
Pertuzumab is available in India?
Pertuzumab is the salt name for the drug sold under the brand name Womab.
Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase survival.
It is the first-in-class of a kind of drug called a “HER dimerization inhibitor” — it inhibits the dimerization of HER2 with other HER receptors, which prevents them from signalling in ways that promote cell growth and proliferation.
Side effects in more than half the people taking it include diarrhea, hair loss, and loss of neutrophils; more than 10% experience loss of red blood cells, hypersensitivity or allergic reaction, infusion reactions, decreased appetite, insomnia, distortions in the sense of taste, inflammation of the mouth or lips, constipation, rashes, nail disease, and muscle pain.
Will this product be accessible across all regions of India?
Womab (pertuzumab) can be made available in major Indian cities, including: Delhi, Gurgain, Noida, Chandigarh, Srinagar, Jammu, Hyderabad, Chennai, Bangalore, Ahmedabad, Surat, Mumbai, Pune, Kolkata, Jaipur, Jodhpur, Hyderabad, Lucknow, Patna.
To learn about the cost price of pertuzumab or to order pertuzumab online, please contact:
📞 Ms. Himanshi: 9999156233
📧 Email: sales@aarkpharma.co.in, sales@aarkpharma.com
We ensure genuine quality, secure delivery, and compliance with all buyer requirements.
Aark Pharma network in India (New Delhi | Lucknow | Varanasi | Chandigarh | Kolkata | Patna | Jodhpur)
Prior to consuming any medications, including pertuzumab Injection, it is advisable to seek guidance from a medical professional regarding its therapeutic advantages, usage instructions, and potential side effects.
NEWS / Updates
- Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer
- FDA grants regular approval to pertuzumab for adjuvant treatment of HER2-positive breast cancer
